Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue: +4.13%
EPS: −21.7%
Free cash flow: −63.7%

Quarter to September 2026, against a year earlier

564.88 43.61 −7.17%

Follow UTHR

Alert me

Market cap: $24.3B
P/E: 19.7×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 8/9
Altman Z: 19.55
Beneish M: −2.26
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

United Therapeutics Corporation (UTHR) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, United Therapeutics Corporation (UTHR) trades at a price to free cash flow of 28.0×. Over the past ten years it has ranged from 0.0× (March 2020) to 30.2× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/UTHR/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="United Therapeutics Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/UTHR/metrics/price-to-free-cash-flow">United Therapeutics Corporation (UTHR) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	20.9×	40.60%
FY2024	14.8×	3.48%
FY2023	14.3×	(24.11%)
FY2022	18.9×	(8.08%)
FY2021	20.5×	112.41%
FY2020	9.7×	—
FY2019	0.0×	—
FY2018	8.0×	(52.95%)
FY2017	17.1×	62.77%
FY2016	10.5×	(0.41%)

Period	Price to free cash flow	Change
Sep 2026	26.9×	26.51%
Jun 2026	21.2×	(16.78%)
Mar 2026	25.5×	22.31%
Dec 2025	20.9×	26.19%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 30.2×

Ten-year median 13.3×

Current reading's percentile 100

Company	Price to free cash flow
TAK Takeda Pharmaceutical Co. compare	8.4×
HLN Haleon PLC Sponsored ADR compare	9.2×
VTRS Viatris Inc. compare	10.7×
ZTS Zoetis Inc. compare	14.7×
NBIX Neurocrine Biosciences, Inc. compare	15.7×
UTHR United Therapeutics Corporation	28.0×
ELAN Elanco Animal Health Incorporated compare	33.2×
TEVA Teva Pharmaceutical Industries Ltd. compare	36.6×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

United Therapeutics Corporation (UTHR) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on UTHR

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on UTHR

Stockrow Weekly